Adicet Bio, Inc. Announces Pricing of Public Offering
2024年1月23日 - 1:43PM
ビジネスワイヤ(英語)
Adicet Bio, Inc. (“Adicet”) (Nasdaq: ACET), a clinical stage
biotechnology company discovering and developing allogeneic gamma
delta T cell therapies for autoimmune diseases and cancer, today
announced the pricing of an underwritten public offering of
27,054,667 shares of its common stock and, in lieu of common stock
to certain investors, pre-funded warrants to purchase 8,445,333
shares of common stock. The shares of common stock are being sold
at a public offering price of $2.40 per share and the pre-funded
warrants are being sold at a public offering price of $2.3999 per
pre-funded warrant, which represents the per share public offering
price of each share of common stock minus the $0.0001 per share
exercise price for each pre-funded warrant. Adicet also granted the
underwriters a 30-day option to purchase up to an additional
5,325,000 shares of common stock at the public offering price, less
underwriting discounts and commissions. The gross proceeds from the
offering, before deducting underwriting discounts and commissions
and offering expenses, are expected to be approximately $85.2
million, excluding any exercise of the underwriters' option to
purchase additional shares. All of the securities in the offering
are to be sold by Adicet. The offering is expected to close on or
about January 25, 2024, subject to customary closing
conditions.
The offering is subject to market and other conditions, and
there can be no assurance as to whether or when the offering may be
completed, or as to the actual size or terms of the offering.
Jefferies and Guggenheim Securities are acting as joint
book-running managers for the offering. Truist Securities is also
acting as a joint bookrunner. Wedbush PacGrow and JMP Securities, A
Citizens Company are acting as co-managers.
The securities described above are being offered by Adicet
pursuant to a shelf registration statement that was previously
filed with, and subsequently declared effective on May 9, 2022 by,
the U.S. Securities and Exchange Commission (“SEC”). A preliminary
prospectus supplement relating to and describing the terms of the
offering was filed with the SEC on January 22, 2024. The final
prospectus supplement relating to the offering will be filed with
the SEC and will be available on the SEC’s website at www.sec.gov.
When available, copies of the preliminary prospectus supplement and
the accompanying prospectus relating to the offered securities may
be obtained from: Jefferies LLC, Attention: Equity Syndicate
Prospectus Department, 520 Madison Avenue, New York, NY 10022, by
telephone at (877) 821-7388, or by email at
prospectus_department@Jefferies.com or Guggenheim Securities, LLC,
Attention: Equity Syndicate Department, 330 Madison Avenue, 8th
Floor, New York, NY 10017, by telephone at (212) 518-9544, or by
email at GSEquityProspectusDelivery@guggenheimpartners.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
About Adicet
Adicet Bio, Inc. is a clinical stage biotechnology company
discovering and developing allogeneic gamma delta T cell therapies
for autoimmune diseases and cancer. Adicet is advancing a pipeline
of “off-the-shelf” gamma delta T cells, engineered with chimeric
antigen receptors (CARs), to facilitate durable activity in
patients.
Forward-Looking Statements
This press release contains “forward-looking statements” of
Adicet within the meaning of the Private Securities Litigation
Reform Act of 1995, as amended, including without limitation,
statements related to the anticipated public offering of
securities. These forward-looking statements include, but are not
limited to, those relating to Adicet’s expectations regarding the
anticipated closing of the public offering. Any forward-looking
statements in this press release are based on management’s current
expectations and beliefs of future events, and are subject to a
number of risks and uncertainties that could cause actual results
to differ materially and adversely from those set forth in or
implied by such forward-looking statements. These risks and
uncertainties related to completion of the public offering on the
anticipated terms, or at all, include, but are not limited to,
market conditions and the satisfaction of customary closing
conditions related to the public offering. For a discussion of
these and other risks and uncertainties, and other important
factors, any of which could cause Adicet’s actual results to differ
from those contained in the forward-looking statements, see the
section entitled “Risk Factors” in Adicet’s most recent annual
report on Form 10-K and our periodic reports on Form 10-Q and Form
8-K filed with the SEC, as well as discussions of potential risks,
uncertainties, and other important factors in Adicet’s other
filings with the SEC, including those contained or incorporated by
reference in the preliminary prospectus supplement and accompanying
prospectus related to the offering filed with the SEC. All
information in this press release is as of the date of the release,
and Adicet undertakes no duty to update this information unless
required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240122485713/en/
Adicet Bio, Inc. Investor and Media Contacts Anne
Bowdidge abowdidge@adicetbio.com
Adicet Bio (NASDAQ:ACET)
過去 株価チャート
から 4 2024 まで 5 2024
Adicet Bio (NASDAQ:ACET)
過去 株価チャート
から 5 2023 まで 5 2024